S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
pixel
Log in
NASDAQ:ACAD

ACADIA Pharmaceuticals Stock Forecast, Price & News

$53.34
-0.03 (-0.06 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$52.56
Now: $53.34
$53.90
50-Day Range
$51.26
MA: $53.77
$56.69
52-Week Range
$30.02
Now: $53.34
$58.72
Volume624,762 shs
Average Volume825,044 shs
Market Capitalization$8.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.44
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals logo

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

310th out of 1,928 stocks

Pharmaceutical Preparations Industry

160th out of 774 stocks

Analyst Opinion: 2.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871
Employees580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$339.08 million
Book Value$4.54 per share

Profitability

Net Income$-235,260,000.00

Miscellaneous

Market Cap$8.48 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$53.34
-0.03 (-0.06 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

How has ACADIA Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ACAD shares have increased by 44.7% and is now trading at $53.34.
View which stocks have been most impacted by COVID-19
.

Is ACADIA Pharmaceuticals a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 hold rating, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACADIA Pharmaceuticals stock.
View analyst ratings for ACADIA Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than ACADIA Pharmaceuticals?

Wall Street analysts have given ACADIA Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ACADIA Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as ACADIA Pharmaceuticals' CEO?

1,428 employees have rated ACADIA Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among ACADIA Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for ACADIA Pharmaceuticals
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Monday, November, 9th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.16. The biopharmaceutical company earned $120.58 million during the quarter, compared to the consensus estimate of $118.82 million. ACADIA Pharmaceuticals had a negative net margin of 63.92% and a negative return on equity of 40.35%. The business's quarterly revenue was up 27.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) earnings per share.
View ACADIA Pharmaceuticals' earnings history
.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $430-450 million, compared to the consensus revenue estimate of $443.75 million.

What price target have analysts set for ACAD?

16 brokers have issued 1 year price objectives for ACADIA Pharmaceuticals' stock. Their forecasts range from $42.00 to $72.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $61.25 in the next year. This suggests a possible upside of 14.8% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of ACADIA Pharmaceuticals' key competitors?

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:
  • Mr. Stephen R. Davis, CEO & Director (Age 60, Pay $1.36M)
  • Dr. Srdjan R. Stankovic, Pres (Age 64, Pay $1.23M)
  • Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 41, Pay $689.09k)
  • Mr. Austin D. Kim, Exec. VP, Gen. Counsel & Sec. (Age 57, Pay $700.8k)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 59, Pay $810.41k)
  • Mr. James K. Kihara, VP, Corp. Controller & Principal Accounting Officer (Age 41)
  • Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations
  • Dr. Eliseo Oreste Salinas, Sr. VP, Chief Scientific Officer & Head of External Innovation (Age 65)
  • Mr. Mark C. Johnson, VP of Investor Relations
  • Ms. Stephanie Fagan, Sr. VP of Corp. Affairs & Chief Communications Officer

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.60%), Peregrine Capital Management LLC (0.11%), Wealthstreet Investment Advisors LLC (0.09%), DNB Asset Management AS (0.03%), First Midwest Bank Trust Division (0.01%) and Kestra Advisory Services LLC (0.01%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals
.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, First Midwest Bank Trust Division, Peregrine Capital Management LLC, Profit Investment Management LLC, Exchange Traded Concepts LLC, and Wealthstreet Investment Advisors LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, James M Daly, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Hohimer Wealth Management LLC, Hohimer Wealth Management LLC, Kestra Advisory Services LLC, Sowell Financial Services LLC, and Pacer Advisors Inc..
View insider buying and selling activity for ACADIA Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $53.34.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $8.48 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 580 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.